You are here
Interview with Prof. Dr. Karin Jordan from ESMO 2017: New Data on Anti-Emesis Agents
The substudy of the GAND-Emesis trial by Ruhlmann et al., presented at ESMO 2017, is a very important study in the field of supportive care. Prof. Dr. Jordan explains the focus of the study and what the findings mean for patient care.
The substudy presents data on nausea rates and the impact of nausea on daily functional life of patients receiving radiochemotherapy. This is particularly important in radiochemotherapy where long periods of time are involved, i.e. from the first day of radiochemotherapy until 35 days after the treatment ends. Ruhlmann et al. were able to show that the impact on daily functional life can be reduced with a triple regimen of antiemetics consisting of fosaprepitant, a steroid, and a 5-HT3 receptor antagonist. This means that an optimal antiemetic prophylaxis is needed in order to improve emetic control and the health-related quality of life.
Prof. Dr. Karin Jordan: Dept. of Haematology and Oncology, University Hospital, Heidelberg, Germany.
This interview was recorded at ESMO 2017 which took place in Madrid on September 8-12, 2017.